Global Gastrointestinal Cancer Treatment Market

Gastrointestinal Cancer Treatment Comprehensive Study by Drug Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Therapy (Immunotherapy, Chemotherapy, Targeted Therapy (Sunitinib, Trastuzumab, Imatinib), Hormone Therapy, Adjuvant Chemotherapy, Radiation Therapy, Others), End User (Hospitals and Specialty Clinics, Cancer Research and Treatment Centers, Ambulatory Surgery Centers) Players and Region - Global Market Outlook to 2030

Gastrointestinal Cancer Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 15.62%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gastrointestinal Cancer Treatment
Gastrointestinal cancer is cancer associated with malignant situations of the gastrointestinal tract. The starting symptoms gastrointestinal cancer are abdominal pain, nausea, vomiting, feeling full after eating only a small amount of food, loss of appetite and others. High consumption high salty and smoked foods may cause gastrointestinal cancer. Thus, increasing consumption of salty and smoked foods in developing countries like China and India is fueling the growth of the market. Additionally, the high availability of gastrointestinal cancer treatment centers across the globe and an introduction of premium-priced therapies for advanced gastrointestinal cancer treatment have been supplementing the overall growth of the market. However, high cost associated with gastrointestinal treatment and lack of treatment facilities in many geographical regions such as the Middle East and South Africa are the factors that have been limiting the growth of the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR15.62%


To entice more end users, market players are focusing on providing Gastrointestinal Cancer Treatment of higher quality while adhering to all regulatory standards. The service providers are also concentrating on the implementation of numerous advanced technologies. Furthermore, the numerous industry profits have led to the entry of new players, raising the level of rivalry in an already competitive market. The Gastrointestinal Cancer Treatment market is currently expanding due to the increasing number of technological advancement. Some of the key players in this market follow strategies, which include new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions.The Players having a strong hold in the market are Amgen Limited & Amgen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Gastrointestinal Cancer Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen Limited & Amgen Ireland Limited (Ireland), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), GlaxoSmithKline plc. (United Kingdom), Celgene Corporation (United States), Pfizer Inc. (United States), Sanofi (France) and Novartis AG. (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Boston Scientific Corporation (United States), Otsuka Holdings (Japan) and CONMED Corporation (United States).

Segmentation Overview
AMA Research has segmented the market of Global Gastrointestinal Cancer Treatment market by and Region.



On the basis of geography, the market of Gastrointestinal Cancer Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Doxorubicin Hydrochloride will boost the Gastrointestinal Cancer Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy, the sub-segment i.e. Immunotherapy will boost the Gastrointestinal Cancer Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals and Specialty Clinics will boost the Gastrointestinal Cancer Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
An Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Cancer Treatment

Market Growth Drivers:
Growing Number of People Suffering From Gastrointestinal Cancer due to Increasing Consumption High Salty and Smoked Foods and High Availability of Gastrointestinal Cancer Treatment Centers across the Globe

Challenges:
Lack of Treatment Facilities in Many Geographical Regions such as the Middle East and South Africa

Restraints:
High Cost Associated with Gastrointestinal Treatment and Intense Competition among Key Players

Opportunities:
Increasing obese Population across the globe and Increasing Government Initiative and Funding for Developing Healthcare Infrastructure

Market Leaders and their expansionary development strategies
On December 2023, FUJIFILM India proudly announces its partnership with GVN Hospital to introduce a groundbreaking mobile endoscopy unit called Endo Bus, revolutionizing the early detection of gastrointestinal (GI) cancer.
On November 8, 2023, the regulatory agency approved fruquintinib for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
As Vice President, in 2016, Joe Biden launched the Cancer Moonshot with the mission to accelerate the rate of progress against cancer. The cancer and patient community and medical researchers responded with tremendous energy and ingenuity. February 2022, President Biden is reigniting the Cancer Moonshot with renewed White House leadership of this effort.

Key Target Audience
Gastrointestinal Cancer Treatment Providers, Government Associations and Agencies, Private Research Organization, Upstream and Downstream Vendors, Potential Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drug Type
  • Doxorubicin Hydrochloride
  • Sunitinib
  • Docetaxel
  • Mitomycin
  • Fluorouracil
  • Imatinib
  • Trastuzumab

By Therapy
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy (Sunitinib, Trastuzumab, Imatinib)
  • Hormone Therapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Others

By End User
  • Hospitals and Specialty Clinics
  • Cancer Research and Treatment Centers
  • Ambulatory Surgery Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of People Suffering From Gastrointestinal Cancer due to Increasing Consumption High Salty and Smoked Foods
      • 3.2.2. High Availability of Gastrointestinal Cancer Treatment Centers across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Lack of Treatment Facilities in Many Geographical Regions such as the Middle East and South Africa
    • 3.4. Market Trends
      • 3.4.1. An Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gastrointestinal Cancer Treatment, by Drug Type, Therapy, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gastrointestinal Cancer Treatment (Value)
      • 5.2.1. Global Gastrointestinal Cancer Treatment by: Drug Type (Value)
        • 5.2.1.1. Doxorubicin Hydrochloride
        • 5.2.1.2. Sunitinib
        • 5.2.1.3. Docetaxel
        • 5.2.1.4. Mitomycin
        • 5.2.1.5. Fluorouracil
        • 5.2.1.6. Imatinib
        • 5.2.1.7. Trastuzumab
      • 5.2.2. Global Gastrointestinal Cancer Treatment by: Therapy (Value)
        • 5.2.2.1. Immunotherapy
        • 5.2.2.2. Chemotherapy
        • 5.2.2.3. Targeted Therapy (Sunitinib, Trastuzumab, Imatinib)
        • 5.2.2.4. Hormone Therapy
        • 5.2.2.5. Adjuvant Chemotherapy
        • 5.2.2.6. Radiation Therapy
        • 5.2.2.7. Others
      • 5.2.3. Global Gastrointestinal Cancer Treatment by: End User (Value)
        • 5.2.3.1. Hospitals and Specialty Clinics
        • 5.2.3.2. Cancer Research and Treatment Centers
        • 5.2.3.3. Ambulatory Surgery Centers
      • 5.2.4. Global Gastrointestinal Cancer Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Gastrointestinal Cancer Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen Limited & Amgen Ireland Limited (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Celgene Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gastrointestinal Cancer Treatment Sale, by Drug Type, Therapy, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gastrointestinal Cancer Treatment (Value)
      • 7.2.1. Global Gastrointestinal Cancer Treatment by: Drug Type (Value)
        • 7.2.1.1. Doxorubicin Hydrochloride
        • 7.2.1.2. Sunitinib
        • 7.2.1.3. Docetaxel
        • 7.2.1.4. Mitomycin
        • 7.2.1.5. Fluorouracil
        • 7.2.1.6. Imatinib
        • 7.2.1.7. Trastuzumab
      • 7.2.2. Global Gastrointestinal Cancer Treatment by: Therapy (Value)
        • 7.2.2.1. Immunotherapy
        • 7.2.2.2. Chemotherapy
        • 7.2.2.3. Targeted Therapy (Sunitinib, Trastuzumab, Imatinib)
        • 7.2.2.4. Hormone Therapy
        • 7.2.2.5. Adjuvant Chemotherapy
        • 7.2.2.6. Radiation Therapy
        • 7.2.2.7. Others
      • 7.2.3. Global Gastrointestinal Cancer Treatment by: End User (Value)
        • 7.2.3.1. Hospitals and Specialty Clinics
        • 7.2.3.2. Cancer Research and Treatment Centers
        • 7.2.3.3. Ambulatory Surgery Centers
      • 7.2.4. Global Gastrointestinal Cancer Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gastrointestinal Cancer Treatment: by Drug Type(USD Million)
  • Table 2. Gastrointestinal Cancer Treatment Doxorubicin Hydrochloride , by Region USD Million (2018-2023)
  • Table 3. Gastrointestinal Cancer Treatment Sunitinib , by Region USD Million (2018-2023)
  • Table 4. Gastrointestinal Cancer Treatment Docetaxel , by Region USD Million (2018-2023)
  • Table 5. Gastrointestinal Cancer Treatment Mitomycin , by Region USD Million (2018-2023)
  • Table 6. Gastrointestinal Cancer Treatment Fluorouracil , by Region USD Million (2018-2023)
  • Table 7. Gastrointestinal Cancer Treatment Imatinib , by Region USD Million (2018-2023)
  • Table 8. Gastrointestinal Cancer Treatment Trastuzumab , by Region USD Million (2018-2023)
  • Table 9. Gastrointestinal Cancer Treatment: by Therapy(USD Million)
  • Table 10. Gastrointestinal Cancer Treatment Immunotherapy , by Region USD Million (2018-2023)
  • Table 11. Gastrointestinal Cancer Treatment Chemotherapy , by Region USD Million (2018-2023)
  • Table 12. Gastrointestinal Cancer Treatment Targeted Therapy (Sunitinib, Trastuzumab, Imatinib) , by Region USD Million (2018-2023)
  • Table 13. Gastrointestinal Cancer Treatment Hormone Therapy , by Region USD Million (2018-2023)
  • Table 14. Gastrointestinal Cancer Treatment Adjuvant Chemotherapy , by Region USD Million (2018-2023)
  • Table 15. Gastrointestinal Cancer Treatment Radiation Therapy , by Region USD Million (2018-2023)
  • Table 16. Gastrointestinal Cancer Treatment Others , by Region USD Million (2018-2023)
  • Table 17. Gastrointestinal Cancer Treatment: by End User(USD Million)
  • Table 18. Gastrointestinal Cancer Treatment Hospitals and Specialty Clinics , by Region USD Million (2018-2023)
  • Table 19. Gastrointestinal Cancer Treatment Cancer Research and Treatment Centers , by Region USD Million (2018-2023)
  • Table 20. Gastrointestinal Cancer Treatment Ambulatory Surgery Centers , by Region USD Million (2018-2023)
  • Table 21. South America Gastrointestinal Cancer Treatment, by Country USD Million (2018-2023)
  • Table 22. South America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 23. South America Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 24. South America Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 25. Brazil Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 26. Brazil Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 27. Brazil Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 28. Argentina Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 29. Argentina Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 30. Argentina Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 31. Rest of South America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 32. Rest of South America Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 33. Rest of South America Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 34. Asia Pacific Gastrointestinal Cancer Treatment, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 36. Asia Pacific Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 37. Asia Pacific Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 38. China Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 39. China Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 40. China Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 41. Japan Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 42. Japan Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 43. Japan Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 44. India Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 45. India Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 46. India Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 47. South Korea Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 48. South Korea Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 49. South Korea Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 50. Taiwan Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 51. Taiwan Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 52. Taiwan Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 53. Australia Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 54. Australia Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 55. Australia Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 59. Europe Gastrointestinal Cancer Treatment, by Country USD Million (2018-2023)
  • Table 60. Europe Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 61. Europe Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 62. Europe Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 63. Germany Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 64. Germany Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 65. Germany Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 66. France Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 67. France Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 68. France Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 69. Italy Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 70. Italy Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 71. Italy Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 72. United Kingdom Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 73. United Kingdom Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 74. United Kingdom Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 75. Netherlands Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 76. Netherlands Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 77. Netherlands Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 78. Rest of Europe Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 79. Rest of Europe Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 80. Rest of Europe Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 81. MEA Gastrointestinal Cancer Treatment, by Country USD Million (2018-2023)
  • Table 82. MEA Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 83. MEA Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 84. MEA Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 85. Middle East Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 86. Middle East Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 87. Middle East Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 88. Africa Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 89. Africa Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 90. Africa Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 91. North America Gastrointestinal Cancer Treatment, by Country USD Million (2018-2023)
  • Table 92. North America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 93. North America Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 94. North America Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 95. United States Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 96. United States Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 97. United States Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 98. Canada Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 99. Canada Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 100. Canada Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 101. Mexico Gastrointestinal Cancer Treatment, by Drug Type USD Million (2018-2023)
  • Table 102. Mexico Gastrointestinal Cancer Treatment, by Therapy USD Million (2018-2023)
  • Table 103. Mexico Gastrointestinal Cancer Treatment, by End User USD Million (2018-2023)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Gastrointestinal Cancer Treatment: by Drug Type(USD Million)
  • Table 115. Gastrointestinal Cancer Treatment Doxorubicin Hydrochloride , by Region USD Million (2025-2030)
  • Table 116. Gastrointestinal Cancer Treatment Sunitinib , by Region USD Million (2025-2030)
  • Table 117. Gastrointestinal Cancer Treatment Docetaxel , by Region USD Million (2025-2030)
  • Table 118. Gastrointestinal Cancer Treatment Mitomycin , by Region USD Million (2025-2030)
  • Table 119. Gastrointestinal Cancer Treatment Fluorouracil , by Region USD Million (2025-2030)
  • Table 120. Gastrointestinal Cancer Treatment Imatinib , by Region USD Million (2025-2030)
  • Table 121. Gastrointestinal Cancer Treatment Trastuzumab , by Region USD Million (2025-2030)
  • Table 122. Gastrointestinal Cancer Treatment: by Therapy(USD Million)
  • Table 123. Gastrointestinal Cancer Treatment Immunotherapy , by Region USD Million (2025-2030)
  • Table 124. Gastrointestinal Cancer Treatment Chemotherapy , by Region USD Million (2025-2030)
  • Table 125. Gastrointestinal Cancer Treatment Targeted Therapy (Sunitinib, Trastuzumab, Imatinib) , by Region USD Million (2025-2030)
  • Table 126. Gastrointestinal Cancer Treatment Hormone Therapy , by Region USD Million (2025-2030)
  • Table 127. Gastrointestinal Cancer Treatment Adjuvant Chemotherapy , by Region USD Million (2025-2030)
  • Table 128. Gastrointestinal Cancer Treatment Radiation Therapy , by Region USD Million (2025-2030)
  • Table 129. Gastrointestinal Cancer Treatment Others , by Region USD Million (2025-2030)
  • Table 130. Gastrointestinal Cancer Treatment: by End User(USD Million)
  • Table 131. Gastrointestinal Cancer Treatment Hospitals and Specialty Clinics , by Region USD Million (2025-2030)
  • Table 132. Gastrointestinal Cancer Treatment Cancer Research and Treatment Centers , by Region USD Million (2025-2030)
  • Table 133. Gastrointestinal Cancer Treatment Ambulatory Surgery Centers , by Region USD Million (2025-2030)
  • Table 134. South America Gastrointestinal Cancer Treatment, by Country USD Million (2025-2030)
  • Table 135. South America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 136. South America Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 137. South America Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 138. Brazil Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 139. Brazil Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 140. Brazil Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 141. Argentina Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 142. Argentina Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 143. Argentina Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 144. Rest of South America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 145. Rest of South America Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 146. Rest of South America Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 147. Asia Pacific Gastrointestinal Cancer Treatment, by Country USD Million (2025-2030)
  • Table 148. Asia Pacific Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 149. Asia Pacific Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 150. Asia Pacific Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 151. China Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 152. China Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 153. China Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 154. Japan Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 155. Japan Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 156. Japan Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 157. India Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 158. India Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 159. India Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 160. South Korea Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 161. South Korea Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 162. South Korea Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 163. Taiwan Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 164. Taiwan Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 165. Taiwan Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 166. Australia Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 167. Australia Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 168. Australia Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 169. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 170. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 172. Europe Gastrointestinal Cancer Treatment, by Country USD Million (2025-2030)
  • Table 173. Europe Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 174. Europe Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 175. Europe Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 176. Germany Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 177. Germany Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 178. Germany Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 179. France Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 180. France Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 181. France Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 182. Italy Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 183. Italy Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 184. Italy Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 185. United Kingdom Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 186. United Kingdom Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 187. United Kingdom Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 188. Netherlands Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 189. Netherlands Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 190. Netherlands Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 191. Rest of Europe Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 192. Rest of Europe Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 193. Rest of Europe Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 194. MEA Gastrointestinal Cancer Treatment, by Country USD Million (2025-2030)
  • Table 195. MEA Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 196. MEA Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 197. MEA Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 198. Middle East Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 199. Middle East Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 200. Middle East Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 201. Africa Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 202. Africa Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 203. Africa Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 204. North America Gastrointestinal Cancer Treatment, by Country USD Million (2025-2030)
  • Table 205. North America Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 206. North America Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 207. North America Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 208. United States Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 209. United States Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 210. United States Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 211. Canada Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 212. Canada Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 213. Canada Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 214. Mexico Gastrointestinal Cancer Treatment, by Drug Type USD Million (2025-2030)
  • Table 215. Mexico Gastrointestinal Cancer Treatment, by Therapy USD Million (2025-2030)
  • Table 216. Mexico Gastrointestinal Cancer Treatment, by End User USD Million (2025-2030)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gastrointestinal Cancer Treatment: by Drug Type USD Million (2018-2023)
  • Figure 5. Global Gastrointestinal Cancer Treatment: by Therapy USD Million (2018-2023)
  • Figure 6. Global Gastrointestinal Cancer Treatment: by End User USD Million (2018-2023)
  • Figure 7. South America Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 8. Asia Pacific Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 9. Europe Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 10. MEA Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 11. North America Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 12. Global Gastrointestinal Cancer Treatment share by Players 2023 (%)
  • Figure 13. Global Gastrointestinal Cancer Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Gastrointestinal Cancer Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Amgen Limited & Amgen Ireland Limited (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Amgen Limited & Amgen Ireland Limited (Ireland) Revenue: by Geography 2023
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 20. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 24. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 26. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi (France) Revenue: by Geography 2023
  • Figure 34. Novartis AG. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG. (Switzerland) Revenue: by Geography 2023
  • Figure 36. Global Gastrointestinal Cancer Treatment: by Drug Type USD Million (2025-2030)
  • Figure 37. Global Gastrointestinal Cancer Treatment: by Therapy USD Million (2025-2030)
  • Figure 38. Global Gastrointestinal Cancer Treatment: by End User USD Million (2025-2030)
  • Figure 39. South America Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 40. Asia Pacific Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 41. Europe Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 42. MEA Gastrointestinal Cancer Treatment Share (%), by Country
  • Figure 43. North America Gastrointestinal Cancer Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen Limited & Amgen Ireland Limited (Ireland)
  • Bristol-Myers Squibb Company (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Celgene Corporation (United States)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Novartis AG. (Switzerland)
Additional players considered in the study are as follows:
Boston Scientific Corporation (United States) , Otsuka Holdings (Japan) , CONMED Corporation (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 164 Pages 66 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gastrointestinal Cancer Treatment Market Quantitative research analysis
Global Gastrointestinal Cancer Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen Limited & Amgen Ireland Limited (Ireland), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), GlaxoSmithKline plc. (United Kingdom), Celgene Corporation (United States), Pfizer Inc. (United States), Sanofi (France) and Novartis AG. (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"An Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Cancer Treatment" is seen as one of major influencing trends for Gastrointestinal Cancer Treatment Market during projected period 2023-2030.
The Gastrointestinal Cancer Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Gastrointestinal Cancer Treatment Market to reach USD4.82 Million by 2030.

Know More About Global Gastrointestinal Cancer Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Veterinary Medication Comprehensive Study by Type (Biologics, Pharmaceuticals, Medicated Feed Additives), Deployment Mode (Oral, Parenteral, Suspension, Topical, Carrier), Distribution Channel (Veter...
$ 3800
Advance Wound Care Comprehensive Study by Type (Hydrogels, Hydrocolloids, Foams, Fabrics, Sponges, Alginates), Application (Inpatient Facilities, Outpatient Facilities), Wound types (Penetrating woun...
$ 3750
Environmental Health And Safety Comprehensive Study by Type (EHS Software, EHS Services), Software (Quality and Risk Assessment, Data Analytics, Cost Management, Environmental Compliance, Energy and...
$ 3750
Ayurvedic Service Comprehensive Study by Type (Health Care, Hair Care, Skin Care, Others), End-users (Women, Men, Kids) Players and Region - Global Market Outlook to 2028
$ 3500
Healthcare Regulatory Affairs Outsourcing Comprehensive Study by End users (Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, Food and Beverage Companies), Services (Regula...
$ 3750
ADME-Tox Screening Systems Comprehensive Study by Type (Instruments, Assay system, Software), Application (Discovery and Development, Biopharmaceutical Production, Drug Screening, Tissue Engineering,...
$ 3750